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ABSTRACT
OBJECTIVE: To describe adverse events following vaccination (AEFV) of children under two 
years old and analyze trend of this events from 2000 to 2013, in the city of Araraquara (SP), Brazil.
METHODS: This is a descriptive study conducted with data of the passive surveillance system of 
AEFV that is available in the electronic immunization registry (EIR) of the computerized medical 
record of the municipal health service ( Juarez System). The study variables were: age, gender, 
vaccine, dose, clinical manifestations and hospitalization. We estimated rates using AEFV as 
numerator and administered doses of vaccines as denominator. The surveillance sensitivity was 
estimated by applying the method proposed by the Centers for Disease Control and Prevention. 
We used Prais-Winsten regression with a significance level of 5.0%.
RESULTS: The average annual rate of AEFV was 11.3/10,000 administered doses, however 
without a trend in the study period (p=0.491). Most cases occurred after the first dose (41.7%) 
and among children under one year of age (72.6%). Vaccines with pertussis component, yellow 
fever and measles-mumps-rubella were the most reactogenic. We highlighted the rates of 
hypotonic-hyporesponsive episodes and convulsion that were 4.1/10,000 and 1.5/10,000 doses 
of vaccines with pertussis component, respectively, most frequently in the first dose; 60,0% of 
cases presented symptoms in the first 24 hours after vaccination, however, 18.6% showed after 
96 hours. The sensitivity of surveillance was 71.9% and 78.9% for hypotonic-hyporesponsive 
episodes and convulsion, respectively.
CONCLUSIONS: The EIR-based AEFV surveillance system proved to be useful and highly 
sensitive to describe the safety profile of vaccines in a medium-sized city. It was also shown that 
the significant increase of the vaccines included in the basic vaccination schedule in childhood 
in the last decade did not alter the high safety standard of the National Immunization Program.
DESCRIPTORS: Vaccines, adverse effects. Electronic Health Records, utilization. Immunization 
Programs. Epidemiological Surveillance.
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INTRODUCTION
Vaccination actions with the National Immunization Program (NIP) have contributed 
to a significant reduction in the burden of vaccine-preventable diseases in Brazil8. 
As the risk perception of these diseases decreases as a result of successful immunization 
programs, the perceived risk of vaccine-preventable diseases (adverse events following 
immunization – AEFI) may increase, decreasing adherence to vaccination and, consequently, 
creating conditions for resurgence of diseases already controlled4.
In 2003, the World Health Organization (WHO) established a comprehensive surveillance 
system to ensure the safety of vaccines administered in national immunization programs22. 
In Brazil, the state of São Paulo evaluates the AEFI since 1984, an initiative that became 
national in 1998 with the implementation of the passive surveillance system of AEFI by 
the NIP. The surveillance of AEFI is aimed at correcting programmatic errors, identifying 
the existence of specific more reactive batches, investigating rare or unknown events, and 
studying associated factors to maintain the public confidence in the immunization program22.
Currently, the Information System of the NIP (IS-NIP) is in the process of being implemented 
in Brazil, which is a database on vaccination that also aggregates the Information System 
of AEFI (IS-AEFI), with online record on the notification, investigation, management, and 
final classification of these events.
Since 1987, the municipality of Araraquara (state of São Paulo) has an electronic immunization 
registry (EIR), in which individual vaccination data and notifications on AEFI are stored, from 
the initiative of the Special Health Service of Araraquara (SESA) of the Faculdade de Saúde 
Pública of the Universidade de São Paulo and technical support of the Information Technology 
Center of São Carlos (CeTI-SC). This EIR is one of the components of the electronic medical 
record called Juarez System and the first EIR in Brazil; however, despite almost three decades 
of use, it has been the subject of few publications. Its evaluation is useful to provide subsidies 
to other municipal EIR that develop similar initiatives, as well as to the IS-AEFI of the NIP.
Thus, this study aimed to describe the AEFI in children aged ≤ 24 months and analyze their 
tendency, in the municipality of Araraquara, from 2000 to 2013, using the EIR of the Juarez System.
METHODS
This is a descriptive study with a trend analysis focused on the frequency and distribution 
of cases reported and confirmed in the passive surveillance system of AEFI in children up 
to 24 months of age living in the municipality of Araraquara, state of São Paulo, Brazil, from 
2000 to 2013.
The municipality of Araraquara has a population of approximately 210,000 inhabitants, 
with approximately 3,000 live births per year; 97.2% of its population is urban and the 
Municipal Human Development Index is 0.815. In relation to health equipment, Araraquara 
has 11 traditional primary health units, 16 units with Family Health Strategy (coverage of 
approximately 40.0% of the population), three general hospitals, two emergency units, one 
psychiatric hospital, and one specialty outpatient clinic. The municipality has a successful 
vaccination program and has high vaccine coverage, so that vaccine-preventable diseases 
have been controlled since the 1990sa.
The SESA is responsible for the management of the electronic medical record of the municipal 
health system (Juarez System), which includes the EIR as one of its components, which can 
identify individuals with late vaccines and, therefore, summon them to update it. The EIR 
of the Juarez System is used by all health services in Araraquara, with online access since 
2012, so that health professionals can verify and record vaccination actions, including AEFI 
notifications, in real time. Before 2012, the record of AEFI was carried out exclusively by the 
staff (nurses, nursing technicians, and administrative personnel) of the SESA. Currently, the 
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SESA still receives, verifies, and stores all the AEFI notification records of the municipality 
of Araraquara and registers the notification in the Juarez System whenever this procedure 
is not carried out by the service unit.
The data from this research were collected from the passive surveillance system of AEFI of 
the municipality of Araraquara, and they are available in the database of the Juarez System 
(date of birth, sex, date of vaccination, date of onset of symptoms, vaccine, and dose). 
Data on clinical manifestations and hospitalization were only reported in the notification 
records of AEFI, which were searched in order to supplement information that was missing 
in the Juarez System.
For the confirmation of cases, the municipal surveillance of AEFI observed the specific 
criteria for each type of event established in a technical document of the NIP – Ministry of 
Healthb. Severe AEFI were evaluated and confirmed by one physician of the SESA, and the 
other types were evaluated and confirmed by professionals of the network of health services 
of the municipality.
In this study, after analyzing the notification records, the confirmed cases of AEFI were 
classified as events with local or systemic manifestations. On the notification of more than 
one AEFI for the same child and dose of vaccine, we considered them as a single case with 
two or fewer events.
The vaccines used during the study period generally had the same origin, most of which were 
produced in Brazil by the Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – FIOCRUZ 
(diphtheria-tetanus-pertussis (whole cell) [DTPw], Haemophilus influenzae b, tetravalent, 
yellow fever, 10-valent pneumococcal conjugate, oral and inactivated polio, rotavirus, and 
measles-mumps-rubella [MMR]), Instituto Butantan (DTPw, hepatitis B, and influenza), and 
Fundação Ataulpho de Paiva (BCG). The yellow fever vaccine is based on a live, attenuated viral 
strain, 17D or equivalent, grown on embryonated chicken eggs. The most recently introduced 
vaccines in the Brazilian calendar follow the processes of technology transfer.
The method proposed by the Centers for Disease Control and Prevention was used to estimate 
the sensitivity of the surveillance of AEFI in Araraquara3. For this purpose, we used the 
rates of hypotonic-hyporesponsive episodes and seizure after pertussis vaccine calculated 
in this study comparing them with those obtained by the study of Martins et al.18, which 
was considered as a reference for this comparison (gold standard). The aforementioned 
study18 has estimated the incidence of these events from the active surveillance of 21,064 
children within 48 hours after administering the diphtheria-tetanus-pertussis (whole cell) 
and Haemophilus influenzae b vaccines at health centers in the city of Rio de Janeiro, Brazil. 
Martins et al.18 have used a vaccine of the same origin as that administered in Araraquara 
during the period of this study.
The data were entered into the database and then analyzed using the software Stata 13. 
We estimated the rates of AEFI cases using the cases of adverse events as numerator and 
the number of doses of vaccine administered as denominator. We also estimated the ratio 
between the number of doses administered and the occurrence of a case by dividing the 
number of doses by the number of AEFI cases.
The trend analysis of the rates of AEFI was performed using a linear regression model for time 
series with the Prais-Winsten method, in order to minimize the first order autocorrelation of 
residuals1. The dependent variable was the rate of AEFI cases, and the independent variable 
was the calendar year. We considered a significance level of 5%, and we carried out a residue 
analysis to verify the suitability of the final model.
This study was approved by the Research Ethics Committee of the Faculdade de Saúde 
Pública of the Universidade de São Paulo (Process 29516814.1.0000.5421), according to 
the recommendations of Resolution 466 of 2012 – National Health Council for Scientific 
Research in Human Beings.
b Ministério da Saúde (BR), 
Secretaria de Vigilância em 
Saúde, Departamento de 
Vigilância das Doenças 
Transmissíveis. Manual de 
vigilância epidemiológica de 
eventos adversos pós-vacinação. 
3. ed. Brasília (DF); 2014.
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RESULTS
From 2000 to 2013, 42,735 children living in Araraquara were registered in the Juarez System, 
with an average of 3,025 births per year. In this period, 763,548 doses of vaccines were 
administered. The number of doses administered per year in children up to 24 months of 
age ranged from 40,611 in 2007 to 77,247 in 2011.
Figure 1 presents the scheme of the selection of AEFI cases recorded in the Juarez System 
and included in this study. We identified 2,638 notifications in the period from 2000 to 
2013 and, after the analysis of the consistency of the database (removal of duplicates), we 
considered 2,608 notifications among persons of all age groups. We found 1,438 reports for 
children up to 24 months of age, of which 864 (60.1%) were confirmed cases (mean annual 
rate of 11.3/10,000 doses of any vaccine, with no trend – p = 0.491), with 54.0% of the cases 
being in males and 72.6% in children under 12 months of age. Of the confirmed cases, 360 
(41.7%) occurred after the first dose of the vaccine.
Figure 2 shows the distribution by quarter/year of the number of doses administered and the 
rates of AEFI cases per 10,000 doses, specifying whether the dose administered was the first 
AEFI: adverse events following immunization
Figure 1. Scheme of the selection of AEFI cases recorded in the Juarez System and included in the study. 
Araraquara, state of São Paulo, Brazil, 2000 to 2013.
Total number of AEFI
2,638
AEFI in children up to 2 years of age
1,438
2,608








AEFI: adverse events following immunization
Figure 2. Distribution of the number of doses administered and rates of AEFI cases in the first dose and other doses per 10,000 doses, 
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one or the other ones. In general, the second quarter of each year has the highest number 
of doses administered. There was an increasing trend in the number of doses administered 
(p = 0.041), especially after 2010, when two new routine vaccines (meningococcal C conjugate 
vaccine and 10-valent pneumococcal conjugate vaccine) and one campaign vaccine for 
influenza were introduced. The rates of AEFI cases for both the first dose and the other 
doses showed seasonal variation.
For 565/864 (65.4%) AEFI cases, we could find the notification records, which were 
manually analyzed, focusing on information regarding the clinical manifestations and 
hospitalizations of the cases. There was no difference in sex and age distribution between 
those with and without a verified record. The 565 cases with analyzed records had 1,251 
clinical manifestations (median = two manifestations per case), of which 419 (33.5%) were 
local and 832 (66.5%) were systemic.
Among the vaccines most frequently associated with AEFI cases, we highlight those 
with pertussis (whole-cell) (DTPw, DTPw-Hib [tetravalent], and DTPw-Hib-Hepatitis B 
[pentavalent]), with a rate of approximately 25/10,000 doses, the yellow fever vaccine, with a rate 
of approximately 6.9/10,000 doses, the MMR vaccine, with a rate of approximately 11.1/10,000 
doses, and the MMRV vaccine, with a rate of approximately 14.1/10,000 doses (Table 1).
Among the 14 AEFI cases of yellow fever, 13 (92.8%) happened in children up to 12 months of 
age. The main clinical manifestations were fever, exanthema, and hypersensitivity, and there 
was no hospitalization. Regarding the MMR vaccine, 53 AEFI cases were reported, of which 
50 (94.3%) occurred in children aged 12–24 months of age and 51 (96.2%) in children with 
primary vaccination. Of these 53 cases, 25 (47.2%) had exanthema, 20 (37.7%) parotitis, 
27 (50.9%) fever, and six (11.3%) adenopathy (data not presented in tables), and we highlight 
that a single case may have presented more than one event.
Table 1. Distribution of AEFI cases, number of doses administered, number of doses per case, and rate 
per 10,000 doses, according to vaccine and route of administration in children up to 24 months of age. 










BCG 41 42,767 1,043 9.6
Hepatitis B 25 120,819 4,833 2.1
DTPw-Hib and Pentavalenta 252 102,689 407 24.5
DTPw 161 62,980 391 25.6
10/13V Pneumococcal Conjugate 28 45,903 1,639 6.1
Men-C-ACYW 17 36,289 2,135 4.7
IPVb 7 8,634 1,233 8.1
OPVc 47 158,367 3,369 3.0
Rotavirus 38 42,974 1,131 8.8
MMR 53 47,718 900 11.1
MMRVd 1 711 711 14.1
Influenza 15 26,152 1,743 5.7
Yellow fever 14 20,170 1,441 6.9
Route of administratione
Intramuscular 505 403,466 799 12.5
Intradermal 41 42,767 1,043 9.6
Subcutaneous 68 68,599 1,009 9.9
Oral 85 201,341 2,369 4.2
a DTPw-Hib or tetravalent: diphtheria-tetanus-pertussis (whole-cell) and Haemophilus influenzae b. Pentavalent: 
diphtheria-tetanus-pertussis (whole-cell) and Haemophilus influenzae b and Hepatitis B.
b IPV: inactivated polio vaccine.
c OPV: oral polio vaccine.
d MMRV: measles, mumps, rubella, and varicella.
e The same individual may have more than one vaccine associated with AEFI.
6Immunization registry and events following immunization Sato APS et al.
https://doi.org/10.11606/S1518-8787.2018052000295
Among the clinical manifestations, local reactions were frequent in all vaccines, with an 
overall rate of 5.5/10,000 doses, including all vaccines (1:1,825 doses), ranging from 12.0/10,000 
doses of pertussis vaccines to 1.0/10,000 doses of yellow fever vaccine. Pain (2.5/10,000 doses) 
and nodule (2.1/10,000 doses) were the most frequent local reactions (Table 2).
Among the systemic reactions, the following stand out: fever (rate of 4.5/10,000 doses, including 
all vaccines), hypotonic-hyporesponsive episode (HHE) (rate of 4.1/10,000 doses of pertussis 
vaccines), and parotitis (rate of 4.2/10,000 doses of measles-mumps-rubella vaccine). The seizure 
rate was 1.5/10,000 doses of pertussis vaccine and the hospitalization rate was 0.2/10,000 doses, 
including all vaccines (sixteen children), mainly associated with HHE and seizure (Table 2).
Regarding the occurrence of HHE (n = 67), there was no difference according to sex. Children 
younger than 12 months of age had a higher frequency (n = 54, 80.6%), especially after the first 
dose of the pertussis vaccine (n = 29, 43.3%). Seizures (n = 25) were more frequent in male 
children and after pertussis vaccine and first booster with DTPw, and eight (32.0%) cases 
were hospitalized. The median age of occurrence for both events was four months (Table 3).
Table 2. Clinical manifestations (n = 1,251a) and hospitalization of adverse effects following immunization, 
number of doses per event, and rate per 10,000 doses, in children up to 24 months of age. Araraquara, 
state of São Paulo, Brazil, 2000 to 2013.
Clinical manifestations/Hospitalization Number of events 
Number of doses 
per event
Rate per 10,000 dosesb
Local
Pain 189 4,040 2.5
Nodule 163 4,684 2.1
Abscess 33 23,138 0.4
Lymphadenitis 33 23,138 0.4
Ulcer 1 763,548 0.1
Systemic
Headache 1 763,548 0.1
Nausea 10 76,355 0.1
Diarrhea 23 33,198 0.3
Vomiting 54 14,140 0.7
Cyanosis 27 28,280 0.4
Malaise 23 33,198 0.3
Irritability 102 7,486 1.3
Sleepiness 44 17,353 0.6
Myalgia 7 109,078 0.1
Exanthema 46 16,599 0.6
Jaundice 1 763,548 0.1
Parotitis 20 38,177 0.3
Fever 344 2,220 4.5
< 38ºC 51 14,971 0.7
38|-|39,4ºC 196 3,896 2,6
≥ 39.5ºC 68 11,229 0.9
Hypotonic-hyporesponsive episode 67 11,396 0.9
Adenoiditis 18 42,419 0.2
Arthralgia 1 763,548 0.1
Hypersensitivity 11 69,413 0.1
Seizure 25 30,542 0.3
Loss of consciousness 6 127,258 0.1
Myelitis 1 763,548 0.1
Paresis 1 763,548 0.1
Hospitalization 16 47,722 0.2
a The 565 cases for which we had information presented 1,251 types of clinical manifestation.
b Rate of AEFI for dose of any vaccine.
7Immunization registry and events following immunization Sato APS et al.
https://doi.org/10.11606/S1518-8787.2018052000295
In order to estimate the sensitivity of the surveillance of AEFI of Araraquara, we compared the 
rates of HHE and seizure (5.7/10,000 and 1.9/10,000 doses of tetravalent vaccine, respectively) 
in a research published by Martins et al.18 with the rates identified in this study (4.1/10,000 
and 1.5/10,000 doses of pertussis vaccine, respectively). Thus, the sensitivity found was 71.9% 
for HHE and 78.9% for seizures.
Regarding the time to onset of the first symptoms, we found 540 cases with this information, 
of which 60.0% (n = 324) presented signs and symptoms in the first 24 hours after vaccination. 
This proportion increased to 82.0% in cases of HHE and seizure. The cases of late AEFI, i.e. 
those that occurred 96 hours after vaccination, accounted for 18.6% (n = 100) of the total 
studied, with emphasis on events following the MMR (n = 31), BCG (n = 28), and tetravalent 
vaccines (DTPw-Hib) (n = 11) (data not shown in tables).
DISCUSSION
The EIR has been used for decades by national immunization programs in developed 
countries that have become very complex because of the diversity of vaccines and 
schedules used routinely4,5. In these countries, the EIR is an important instrument for the 
promotion of high and homogeneous vaccination coverage, as well as for the monitoring of 
immunobiological safety2,22.
This study, to the best of our knowledge, is the first one done in Brazil, analyzing data from an 
EIR for the description of AEFI. It is especially timely, as it provides results that can provide 
support for the current proposal by the NIP of implementing an EIR articulated with an 
information system for AEFI.
Several of its results are relevant, among them, the significant increase of doses administered 
from the rapid expansion of the types of vaccines included in the basic vaccination schedule, 
including in the combined form8. On the other hand, the stability of the rates of AEFI cases, 
verified in the period, suggests that the greater complexity achieved by the NIP, resulting 
from changes in the basic immunization schedule, did not change the safety profile of the 
vaccines included in the NIP schedule.
Table 3. Distribution of hypotonic-hyporesponsive events and seizures in children up to 24 months 
of age who received pertussis vaccine, according to sex, age, dose administered, and hospitalization. 
















Male 33 (49.3) 3.9 2,530 17 (68.0) 2.0 4,911
Female 34 (50.7) 4.1 2,418 8 (32.0) 1.0 10,274
Age
< 12 months 54 (80.6) 4.3 2,320 25 (100) 2.0 5,011
12|-|24 months 13 (19.4) 3.2 3,106 0 (0) - -
Median 4 months 4 months
Dose administered
1st dose 29 (43.3) 6.9 1,451 2 (8.0) 0.5 21,041
2nd dose 16 (23.9) 3.8 2,634 7 (28.0) 1.7 6,020
3rd dose 13 (19.4) 3.1 3,218 7 (28.0) 1.7 5,977
1st booster 9 (13.4) 2.3 4,400 9 (36.0) 2.3 4,400
Hospitalization 7 (10.5) 0.4 23,667 8 (32.0) 0.5 20,709
Total 67 4.1 2,473 25 1.5 6,626
HHE: hypotonic-hyporesponsive episode
* Rate of AEFI per dose of pertussis vaccine (total number of doses = 165,669; number of males = 83,477; number of 
females = 82,192; number of < 12 months = 125,291; number of 12|-| 24 months = 40,378; number of 1st doses = 
42,082; number of 2nd doses = 42,143; number of 3rd doses = 41,839; number of 1st boosters = 39,605). 
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An interesting result is the clear seasonal variation of the rates of AEFI cases found 
in this study. It is worth noting that it is not the result of the use of batches of more 
reatogenic vaccines, since we did not identify changes in the mean annual rates of 
AEFI. In fact, it reflects the sharp rise in the number of doses administered in annual 
vaccination campaigns (such as polio and influenza, the latter after 2010) or specific 
campaigns (such as the measles follow-up campaign in 2000), consequently determining 
a greater concentration of the number of AEFI in time. Similar behavior has been found 
in several studies, including some in Brazil9,11,12. This increase in AEFI in a short period 
of time usually creates a warning to health professionals, increasing the sensitivity of 
the surveillance22.
This study also showed the prevalence of AEFI in the first year of life and higher rates of 
AEFI associated with the pertussis (whole cell), MMR, and yellow fever vaccines. These 
results are consistent with the literature, which indicates a higher frequency of HHE 
and seizure after the administration of the pertussis vaccine, parotitis after the measles-
mumps-rubella vaccine, and reactions such as fever and exanthema after the yellow fever 
vaccine 10,13,15,18. In turn, considering that the risk of AEFI is higher in the first dose6,13,18 and 
that most vaccines are concentrated in the first months of life, the predominance of AEFI 
in this age group is explained.
An important fact was the high sensitivity of the surveillance of AEFI of Araraquara, at 71.9% 
for HHE and 78.9% for seizure. A Brazilian study that carried out this evaluation, considering 
the same study as the “gold standard”18, has found a mean sensitivity of 22.3% and 31.6% for 
HHE and seizure, respectively, with a high variation among states (approximately 3.0% to 
100.0% for HHE and 5.0% to 90.0% for seizures)19. In this way, we can see the potential of the 
EIR of the Juarez System in the surveillance of AEFI.
The disadvantages of this type of passive surveillance of AEFI are partially compensated by the 
use of the EIR as a source. In addition to having a more precise numerator and denominator 
for the estimates of incidence of AEFI, the EIR has information on the child’s previous history 
of vaccination and simultaneous exposure to multiple vaccines22. In addition, the EIR allows 
a more accurate description of AEFI as it records the date of onset of the symptoms, allowing 
the identification of late AEFI. In turn, the indication or not of revaccination of individuals 
who had AEFI in the first dose can be evaluated.
An additional advantage of the EIR is the possibility to implement active surveillance 
systems when the EIR is linked to an electronic record5,14, similarly to the Vaccine Safety 
Datalink of the United States23, or define and detect sentinel AEFI7. Moreover, the EIR can 
be used to generate hypotheses in epidemiological studies and in the articulation with 
other databases2,5,16,17,20,21.
This study has limitations regarding the use of secondary data; however, we consider this 
tool a viable way of capturing the amount of information needed to assess a time series of 
nominal data on child vaccination in a short period of time. In addition, since the registry of 
AEFI in the EIR of the Juarez System is still recent, the availability of the data in the system 
can be improved, such as those referring to the clinical manifestations that needed to be 
searched in health reports. However, the system showed good sensitivity in the surveillance 
of AEFI and the results are consistent with the literature.
We conclude that there was no change in the safety profile of the basic scheme of vaccines 
in the period from 2000 to 2013. This study describes the use of EIR to better evaluate AEFI 
in a medium-sized municipality, highlighting its potential in the surveillance of these events. 
This information is relevant to the ongoing updating of vaccination standards in order to 
ensure the safety and reliability of the NIP, in addition to broadening the academic production 
on the subject. The intention is to contribute with the improvement of the EIR in Brazil, 
either for municipal initiatives of electronic registry with a vaccination component or for 
the implementation of the IS-NIP.
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